Patents by Inventor Steven S. Neben

Steven S. Neben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
    Patent number: 12005120
    Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 11, 2024
    Assignee: Regulus Therapeutics Inc.
    Inventors: Charles R. Allerson, Steven S. Neben, Timothy Wright
  • Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect
    Publication number: 20210170034
    Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
    Type: Application
    Filed: May 7, 2019
    Publication date: June 10, 2021
    Applicant: Regulus Therapeutics Inc.
    Inventors: Charles R. Allerson, Steven S. Neben, Timothy Wright